Home
About
Overview
Sharing Data
ORCID
Help
History (3)
Adalimumab sustains steroid-free remission after 3 years of therapy for Crohn's disease.
Controversies with aminosalicylates in inflammatory bowel disease.
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial.
See All 3 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Controversies with aminosalicylates in inflammatory bowel disease.
Controversies with aminosalicylates in inflammatory bowel disease. Rev Gastroenterol Disord. 2004; 4(3):104-17.
View in:
PubMed
subject areas
Aminosalicylic Acids
Antibodies, Monoclonal
Anti-Inflammatory Agents, Non-Steroidal
Chemoprevention
Colitis, Ulcerative
Colorectal Neoplasms
Crohn Disease
Dose-Response Relationship, Drug
Gastrointestinal Agents
Humans
Infliximab
Mesalamine
Remission Induction
Sulfasalazine
authors with profiles
Stephen B. Hanauer